Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA
Sign Up to like & getrecommendations! Published in 2024 at "Nature Communications"
DOI: 10.1038/s41467-023-44376-8
Abstract: Avapritinib is the only potent and selective inhibitor approved for the treatment of D842V-mutant gastrointestinal stromal tumors (GIST), the most common primary mutation of the platelet-derived growth factor receptor α (PDGFRA). The approval was based… read more here.
Keywords: sar studies; avapritinib based; pocket; pdgfra ... See more keywords